Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Meth...Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Methods:Patients were treated with nab-paclitaxel at a dose of 125 mg/m2 on day 1 and 8,and S-1,80 to 120 mg/day on days 1-14 of a 21-day cycle.Treatments were repeated until disease progression or unacceptable toxicity occurred.The primary endpoint was objective response rate(ORR).The secondary endpoints were median progression-free survival(PFS),overall survival(OS),and adverse events(AEs).Results:The number of patients enrolled were 54,and 51 patients were evaluated for efficacy.A total of 14 patients achieved partial response(PR)with an ORR of 27.5%.The ORR varied by sites,with 53.8%(7/13)for gallbladder carcinoma,18.4%(7/38)for cholangiocarcinoma.The most common grade 3 or 4 toxicities were neutropenia and stomatitis.The median PFS and OS were 6.0 and 13.2 months,respectively.Conclusions:The combination of nab-paclitaxel with S-1 showed explicit antitumor activities and favorable safety profile in advanced BTC and could serve as a potential non-platinum and-gemcitabine-based regimen.展开更多
目的探讨晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效。方法回顾性选取2019年1月—2023年1月歙县人民医院肿瘤内科收治的60例晚期恶性肿瘤患者,依据治疗方法分为替吉奥组和对照组,每组30例。替吉奥组患者接受替吉奥胶囊姑息治疗,对照组患者...目的探讨晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效。方法回顾性选取2019年1月—2023年1月歙县人民医院肿瘤内科收治的60例晚期恶性肿瘤患者,依据治疗方法分为替吉奥组和对照组,每组30例。替吉奥组患者接受替吉奥胶囊姑息治疗,对照组患者接受卡培他滨治疗。统计分析两组患者临床疗效、血清肿瘤标志物水平[血清癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha-fetal protein,AFP)、糖类抗原199(carbohydrate antigen 199,CA199)]、疼痛程度[视觉模拟评分法(Visual Analog Scoring,VAS)]、生存质量[卡式评分标准(Card Rating Scale,KPS)、日常生活能力(Daily Living Ability,ADL)、工具性日常活动能力量表(Instrumental Daily Activity Ability Scale,IADL)、生活质量量表(Quality Of Life Scale,QOL)]、不良反应发生情况、生存期。结果替吉奥组患者的总缓解率83.33%高于对照组,差异有统计学意义(χ^(2)=9.320,P<0.05)。替吉奥组患者的血清AFP、CEA、CA199水平、VAS评分均低于对照组,KPS评分、ADL评分、IADL评分、QOL评分均高于对照组,差异有统计学意义(P<0.05)。替吉奥组患者的不良反应发生率10.00%低于对照组,差异有统计学意义(χ^(2)=4.344,P<0.05)。替吉奥组患者的无进展生存期长于对照组,差异有统计学意义(P<0.05)。结论晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效显著。展开更多
文摘Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Methods:Patients were treated with nab-paclitaxel at a dose of 125 mg/m2 on day 1 and 8,and S-1,80 to 120 mg/day on days 1-14 of a 21-day cycle.Treatments were repeated until disease progression or unacceptable toxicity occurred.The primary endpoint was objective response rate(ORR).The secondary endpoints were median progression-free survival(PFS),overall survival(OS),and adverse events(AEs).Results:The number of patients enrolled were 54,and 51 patients were evaluated for efficacy.A total of 14 patients achieved partial response(PR)with an ORR of 27.5%.The ORR varied by sites,with 53.8%(7/13)for gallbladder carcinoma,18.4%(7/38)for cholangiocarcinoma.The most common grade 3 or 4 toxicities were neutropenia and stomatitis.The median PFS and OS were 6.0 and 13.2 months,respectively.Conclusions:The combination of nab-paclitaxel with S-1 showed explicit antitumor activities and favorable safety profile in advanced BTC and could serve as a potential non-platinum and-gemcitabine-based regimen.
文摘目的探讨晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效。方法回顾性选取2019年1月—2023年1月歙县人民医院肿瘤内科收治的60例晚期恶性肿瘤患者,依据治疗方法分为替吉奥组和对照组,每组30例。替吉奥组患者接受替吉奥胶囊姑息治疗,对照组患者接受卡培他滨治疗。统计分析两组患者临床疗效、血清肿瘤标志物水平[血清癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha-fetal protein,AFP)、糖类抗原199(carbohydrate antigen 199,CA199)]、疼痛程度[视觉模拟评分法(Visual Analog Scoring,VAS)]、生存质量[卡式评分标准(Card Rating Scale,KPS)、日常生活能力(Daily Living Ability,ADL)、工具性日常活动能力量表(Instrumental Daily Activity Ability Scale,IADL)、生活质量量表(Quality Of Life Scale,QOL)]、不良反应发生情况、生存期。结果替吉奥组患者的总缓解率83.33%高于对照组,差异有统计学意义(χ^(2)=9.320,P<0.05)。替吉奥组患者的血清AFP、CEA、CA199水平、VAS评分均低于对照组,KPS评分、ADL评分、IADL评分、QOL评分均高于对照组,差异有统计学意义(P<0.05)。替吉奥组患者的不良反应发生率10.00%低于对照组,差异有统计学意义(χ^(2)=4.344,P<0.05)。替吉奥组患者的无进展生存期长于对照组,差异有统计学意义(P<0.05)。结论晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效显著。
